We reviewed MR-guided high intensity focused ultrasound treatments (MRgFUS) of extra-abdominal desmoid tumors (DTs) in our institution from 02/2013 until 12/2020. The primary endpoints for assessing efficacy are post-treatment change in tumor volume, response based on RECIST and mRECIST; secondary endpoints are change in pain and quality of life. Complications are also reported. Our study demonstrates MRgFUS is an effective treatment option for first line and salvage therapy of desmoid tumors.
This abstract and the presentation materials are available to members only; a login is required.